Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862694 | 1.00 | TSHR (0.46) | TSHRKDM4EMAPK1TDP1SLC6A2 | |
| SCHEMBL11134197 | 0.83 | TSHR (0.39) | TSHRKDM4EMAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL9538964 | 0.79 | TSHR (0.36) | TSHRKDM4EMAPK1TDP1 | |
| SCHEMBL1131400 | 0.78 | CYP2D6 (0.37) | TSHRKDM4EMAPK1TDP1SLC6A2 | |
| SCHEMBL26780682 | 0.76 | CETP (0.36) | TSHRKDM4EMAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL7276708 | 0.74 | CETP (0.35) | TSHRKDM4EMAPK1TDP1 | |
| SCHEMBL2953547 | 0.74 | TSHR (0.39) | TSHRMAPK1TDP1SLC6A2SLC6A4 | |
| SCHEMBL10163389 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL24435891 | 0.71 | TSHR (0.50) | TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18759629 | 0.71 | TSHR (0.50) | TSHRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1529047-B1 | NEW PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060183760-A1 | New purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-08-17 | — | — | US | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325983-A1 | NEW PURINE DERIVATIVES | C5, CYC1, CCNH | TSHR 1257/4885KDM4E 3098/4885MAPK1 993/4885 |
| US-20060183760-A1 | New purine derivatives | C5, CYC1, CCNH | TSHR 1183/4885KDM4E 3050/4885MAPK1 1220/4885 |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CDK1, CDK2, CCND1 | TSHR 649/4885KDM4E 1420/4885MAPK1 149/4885 |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | TSHR 1243/4885KDM4E 989/4885MAPK1 1487/4885 |
| US-20090270427-A1 | PURINE DERIVATIVES | C5, CYC1, CCNH | TSHR 1020/4885KDM4E 3122/4885MAPK1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.